Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking ...

Oil prices fell on Friday on signs demand in China, the world's biggest crude importer, continues to underperform amid its ...

Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...

Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program ...

Key Takeaways Vaccine maker stocks fell in Friday morning trading after president-elect Donald Trump said he would nominate ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

Investors continued to see multiple shades of light red as biotechs continued to struggle in the wake of the postelection ...

How can clinical trial participants be prevented from recording information inaccurately? One solution for pharmaceutical ...

Trace Neuroscience has launched in the U.S. with over $100 million in financing and a goal to develop its UNC13A-targeted treatment for ALS.